In 2022, the market for G-protein coupled receptors (GPCRs) was valued at US$ 3.2 billion. The IMARC Group projects that the market will grow at a compound annual growth rate (CAGR) of 6.52% from 2023 to 2028, when it reaches US$ 4.7 billion.
.jpg
"The Global G-protein Coupled Receptors Market 2018-2028 (USD Billion)")
The global G-protein coupled receptors market was valued at USD 2.35 billion in 2020 and is projected to grow at a CAGR of 6.3% during the forecast period. Factors driving the growth of the G-protein coupled receptors market include the effective identification of pharmaceutically relevant drug candidates, the growing government funding for R&D activities in drug discovery and development and increasing prevalence of chronic diseases.
G-protein-coupled receptors (GPCRs) constitute the largest family of membrane receptors in humans, and ~34% of marketed drugs target this family. Since their discovery, this receptor family has been both pharmacologically and biologically important in the treatment of different pathological conditions. GPCRs contain a common pattern in their basic structures. They consist of seven membrane-spanning domain structures, which they use to sense different signals and stimuli, including light, stress, hormones, peptides, and so forth. The global G-protein coupled receptors market is segmented based on assay type and application.
Regionally, North America accounted for the largest market share of the global G-protein coupled receptors market attributable to increased focus on drug discovery & development activities. Leading players of the global G-protein coupled receptors market include Thermo Fisher Scientific, Inc., QIAGEN, Eurofins Scientific, WuXi AppTec, Abcam plc, Promega Corporation, Perkin Elmer Inc., Merck KGaA, Enzo Biochem Inc., Becton-Dickinson and Company among others.
G-protein Coupled Receptors Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2028 |
| Study Period | 2018-2028 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2028 | USD 4.7 billion |
| Growth Rate | CAGR of 6.52% during 2018-2028 |
| Segment Covered | Assay Type, Application, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Key Players Profiled | Thermo Fisher Scientific, Inc., QIAGEN, Eurofins Scientific, WuXi AppTec, Abcam plc, Promega Corporation, Perkin Elmer Inc., Merck KGaA, Enzo Biochem Inc., Becton-Dickinson and Company among others. |
Key segments of the global G-protein coupled receptors market
Assay Type Overview, (USD Billion)
- Calcium Level Detection Assays
- Radioligand Binding and GTPγS Functional Assays
- cAMP Assays and cGMP Assays
- β-Arrestin Functional Assays
- Reporter Gene Assays
- Other Assay Types
Application Overview, (USD Billion)
- Cardiovascular System
- Central Nervous System
- Oncology
- Other Applications
Regional Overview, (USD Billion)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- GCC
- South Africa
Reasons for the study
- Wide range applications of GPCRs in the treatment for various medical conditions
- Growing demand for GPCR assays in drug discovery studies
- Complexity of the GPCR signaling system
What does the report include?
- The study on the global G-protein coupled receptors market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of assay type and application. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global G-protein coupled receptors market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global G-protein coupled receptors market
Consultants, analysts, researchers, and academicians looking for insights shaping the global G-protein coupled receptors market
G protein-coupled receptors (GPCRs) form the largest family of membrane proteins responsible for communication between the cell and the environment. These proteins recognize extracellular messengers and transduce the signal to the cytosol. GPCRs bind to a wide variety of molecules, including ions, amino acids, peptides, lipids, and nucleotides. They control the activity of enzymes, ion channels and vesicular transport, principally through the catalysis of GDP-GTP exchange on heterotrimeric G proteins. They are involved in diverse biological functions including the senses of smell, taste and sight, and the regulation of appetite, digestion, blood pressure, reproduction and inflammation the reason why they are involved in a wide variety of pathologies. GPCRs have proven to be particularly amenable to modulation by small molecule drugs and are the targets of approximately half of the current prescription drugs, as well as the targets of a large number of therapeutics and GPCRs provide opportunities for the development of new drugs with applications in all clinical fields.
By application the global G-protein coupled receptors market is segmented into cardiovascular system, central nervous system, oncology and others. Central nervous system diseases are most common and prevalent in elderly people worldwide and cause progressive neuronal dysfunction, toxicities, and death. These diseases lead to an irreversible weakening of all brain functions. Alzheimer’s disease (AD), vascular dementia (VaD), frontotemporal dementia (FTD), Parkinson’s disease (PD), and Huntington’s disease (HD) are the prevalent neurodegenerative diseases commonly diagnosed in aged people. The cognitive function in patients is seriously affected during these disease’s progression. Therefore, the age-related decline in cognitive function is a leading challenge in mental health research. Although some symptomatic treatments are available for neurodegenerative diseases, no specific treatments have yet been found. GPCRs are now the most common target used to develop novel therapeutics for neurodegenerative diseases.
North America accounted for the largest share of the global GPCRs market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period.
Cancer is a major public health problem and is the second leading cause of death in the United States and worldwide. Cancer is responsible for over 8.8 and 1.6 million deaths globally and domestically and nearly one in six deaths are attributable to cancer. In the United States, prostate, lung, and colorectal cancers account for 44% of all cases in men, with prostate cancer accounting for one in five new diagnoses. Breast, lung, and colorectal cancers account for one-half of all cases in women, with breast cancer accounting for 29% of new diagnoses. GPCRs are being widely explored to develop novel therapeutics for cancer.